Onco-Innovations Limited (W1H.F)

Onco-Innovations Limited, a pre-clinical stage biotechnology company, develops drug candidates for cancer treatments in Canada. The company's lead product candidate is ONC010, an inhibitor of the DNA repair enzyme polynucleotide kinase 3'-phosphatase (PNKP) in a nanoparticle formulation based on drug delivery technology. It also develops SynoGraph technology, an artificial intelligence-powered tool to accelerate precision oncology breakthroughs and de-risk drug development. In addition, the company engages in research and development activities. It has collaborations with Dalton Pharma Services, the University of Alberta and Cross Cancer Institute, Nucro-Technics Inc., and Avance Clinical Pty Ltd. Onco-Innovations Limited is headquartered in Calgary, Canada.